Companies: 10,795·Total market cap: $144.5T

Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc.

DCPHNASDAQHealthcare

$25.59

+$0.02(+0.08%)

Market Cap$2.2B

P/E Ratio—

52W High$25.61

52W Low$9.9

Avg Volume1.9M

Open$25.56

Beta0.18

Net Income Financials Revenue

Deciphera Pharmaceuticals, Inc. (DCPH) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

DCPH · net income · updated Jun 9, 2026

Core profitability metrics

DCPH · net income · margin · TTM · CAGR

Net income was −$194.9M for FY2023 (fiscal year ending 2023-12-31), down 8.9% year-over-year. Net profit margin was -119.3%.

FY2023 Net Income−$194.9M▼ -8.9% YoY

Trailing 12M (TTM)−$190.4Mtrailing 4 quarters sum

Net Profit Margin-119.3%−$194.9M ÷ $163.4M

YoY Change-8.9%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · DCPH net income history · DCPH profit margin

Annual net income data

DCPH · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2023Loss−$194.9M▼ 8.9%-119.3%$163.4M

FY2022Loss−$178.9M▲ +39.7%-133.5%$134.0M

FY2021Loss−$296.8M▼ 11.4%-308.7%$96.1M

FY2020Loss−$266.5M▼ 39.2%-633.2%$42.1M

FY2019Loss−$191.5M▼ 91.8%-766.0%$25.0M

Net income vs peers (Healthcare)

DCPH vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Deciphera Pharmaceuticals, Inc.YOU

DCPH

−$194.9M-8.9%-119.3%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Deciphera Pharmaceuticals, Inc. (DCPH) reported net income of −$194.9M for FY2023 (fiscal year ending 2023-12-31), down 8.9% year-over-year. The net profit margin was -119.3% — meaning the company kept $-1.19 of every dollar of revenue as profit.

Deciphera Pharmaceuticals, Inc. has not yet achieved annual profitability based on available data (9 fiscal years). The company has reported net losses across all available periods.

Deciphera Pharmaceuticals, Inc.'s net profit margin was -119.3% for FY2023, based on the latest annual results.

Investors sometimes search for "Deciphera Pharmaceuticals, Inc. net worth" — the company's market capitalization is a separate figure from DCPH net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

DCPH net income · 4 questions

Deciphera Pharmaceuticals, Inc. is not currently profitable on an annual basis. The company reported a net loss of $194.9M for FY2023.

is DCPH profitabledoes DCPH make a profitDCPH profitabilityDCPH profitable company

▸ Source: FMP /income-statement · GAAP · Deciphera Pharmaceuticals, Inc. · Deciphera Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026